University of Alberta Researchers Investigate Why Semaglutide Weight Loss Varies by Patient

Medications containing semaglutide do not work the same way for every patient, according to a multidisciplinary research team at the University of Alberta pillars in obesity management, ScienceDaily reported.

The drugs, which include household names like Ozempic and Wegovy, act on the brain to increase feelings of fullness and decrease appetite. Clinical research shows that body weight by an average of 15 percent drops when users take the weekly injections for 68 weeks alongside lifestyle interventions.

Yet the response varies widely across individuals. Researchers at the University of Alberta are investigating whether individual factors such as genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age, and sex explain why some patients respond better than others.

Energy metabolism represents the balance between total calories consumed and total calories burned. When individuals lose weight, their bodies naturally require less energy, but physiological changes can trigger an extra energy-saving mode known as metabolic adaptation or adaptive thermogenesis.

This adaptive response causes the body to burn even fewer calories than expected, much like a dimming light bulb. This mechanism often drives weight-loss plateaus over time.

University of Alberta Researchers Investigate Why Semaglutide Weight Loss Varies by Patient
Photo: EURweb

Researchers are studying whether weight-loss medications influence these metabolic processes directly. A recent review of studies examining GLP-1 therapies and resting energy use found findings that were neutral or inconclusive, leaving the exact impact on energy expenditure as an open question.

Other factors also dictate how well these treatments perform in practice. In a recent head-to-head trial, participants taking tirzepatide lost an average of about 20 percent of their body weight, compared with about 14 percent among those taking semaglutide, EURweb reported.

Lifestyle habits remain critical. Continuing to consume high-calorie foods can blunt the therapeutic effects of the drugs. A 2024 study cited by EURweb demonstrated that adding supervised exercise produced greater weight loss and improved the odds of maintaining it compared to medication alone.

Side effects present another major hurdle for patients. A trial published in the New England Journal of Medicine found that 74.2 percent of GLP-1 participants experienced symptoms such as nausea, diarrhea, and vomiting, while 4.5 percent withdrew from treatment entirely due to severe reactions.

Roy Taylor, an emeritus professor of medicine and metabolism at Newcastle University, said doctors need to be upfront about the risks. “If this is not explained – and especially so if people are taking these drugs without medical supervision, as many people are – then this is a really potent issue,” he said.

Taylor said that early nausea is expected and tends to ease the longer patients stay on the treatment. He also dismissed sleep as a major metabolic factor, describing its effects as trivial and attributing poor sleep in heavier individuals primarily to their weight.

To investigate these discrepancies further, the University of Alberta team is utilizing a whole-room indirect calorimeter—a rare research facility resembling a hotel suite that precisely measures energy use at rest, after eating, and during exercise.

The facility is currently recruiting participants with blood sugar regulation issues, such as insulin resistance or diabetes, who are about to begin semaglutide treatment. Researchers will track their progress over six months to map changes in body weight, composition, and energy utilization.

Identifying how semaglutide alters energy use could help clinicians anticipate non-responders and offer alternative treatments sooner. Current evidence indicates that patients taking or considering semaglutide should incorporate specific lifestyle changes to maximize their chances of success.